Snibe announced on 16 July that it has received the CE mark for the fully automated quantitative serology test for detecting IgG antibodies against SARS-CoV-2 S-RBD (the receptor-binding domain of S protein). Now the new tests are ready to ship to worldwide and available to come into service.  
 
The test, called MAGLUMI? SARS-CoV-2 S-RBD IgG, is designed for the quantitative detection of antibodies to the receptor-binding domain of the S protein, which is believed to neutralize the coronavirus, indicating that they can be an effective measure to assess immunity when compared to antibodies targeting other SARS-CoV-2 proteins.
MAGLUMI? SARS-CoV-2 S-RBD IgG kits have 99.6% specificity and 100% sensitivity at 15 days post-onset of symptom for COVID-19, which can provide more accurate and reasonable results within 30 mins with ONLY 10uL sample volume. Due to the strong correlation to neutralizing antibodies, the S-RBD IgG concentration can be an effective assistance for clinicians to make a better clinical diagnosis and treatment.
The new MAGLUMI? SARS-CoV-2 S-RBD IgG tests can be run on a global installed base of 13000 MAGLUMI? CLIA systems, including MAGLUMI? X8 immunoassay analyzer, which can run up to 14400 tests per day. Multiple MAGLUMI? X8 could be connected to form a modular system to meet the high demands of large hospitals, especially during the COVID-19 pandemic period.
 
Snibe never stops pursuing high-quality solutions for human health. In these difficult times, Snibe stands together with governments and all those working people to overcome the pandemic. 

Related Product News：

1. Snibe launched MAGLUMI? SARS-CoV-2 Neutralizing Antibody
2. The world's first 2019-nCoV (SARS-CoV-2) CLIA Kits received CE mark.
3. Molecision SARS-CoV-2 RT-PCR Assay product features and benefits.